Pharma: a tale of rising demand and squeezed prices

Download the Document

Pharmaceuticals Sector Risk Report


Spending on prescription drugs is on an upward trajectory worldwide, and especially in Western Europe and the US. Pharma group profits rose by 2.9% in 2017. Reasons include ageing populations, changing lifestyles and pressure to access innovative treatments, and the rise comes despite the efforts of governments to control healthcare spending. The US situation is particularly uncertain, with the Trump administration’s attempts to repeal ‘Obamacare’ meeting difficulties.


Coface Regional Sector Risk Assessment

Strengths and weaknesses

Coface analysts predict research and development by pharmaceutical companies to pick up in 2018, and for prescription sales to grow – by 4% France, UK, Germany, Italy and Spain for example. This is driven by the rise in specialist drugs, which now amount to over a third of the total. Everywhere pharmaceutical companies are under pressure to provide discounts and lower prices by governments facing increasing demand. In the US alone, health insurance costs are likely to rise by as much as 18% in 2018.

Throughout the world healthcare provision is in flux and prices are being driven down. That’s why any company dealing with the pharma sector needs to have the best business data and insight on tap. It all comes free when you’re a Coface credit insurance policy holder.

Sign up for the latest news


United States: two-speed business bankruptcies

As the COVID-19 epidemic hits the United States very hard, Coface forecasts in its baseline scenario that the country's GDP will contract by 5.6% in 2020, before rebounding by 3.3% in 2021. Nevertheless, this forecast is

View Resource

Asia-Pacific Corporate Payment Survey 2020: COVID-19 will overturn last year’s initial recovery

Coface’s annual Asia Corporate Payment Survey evaluates the payment behaviour of companies across nine economies in Asia Pacific. Data collection took place during the fourth quarter of 2019, before the COVID-19 pandemic, and

View Resource

Are corporate balance sheets in Spain and Italy ready for the covid-19 shock?

Although the second quarter of 2020 is shaping up to be the most challenging period of the year, there are now good reasons to think that the road to recovery will be long and arduous. Despite immediate tax deferrals, liquidity

View Resource